Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer

Published:2024 Issue: Volume:35 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Huang Shuai¹^ORCID,Sheng Guihua¹^ORCID,Lv Qiubo¹^ORCID,Li Ye¹^ORCID,Meng Qingwei¹^ORCID,Gao Xuexiao¹^ORCID,Shang Zhiyuan¹^ORCID

Affiliation:

1. Department of Gynecology and Obstetrics, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Publisher

XMLink

Link

https://ejgo.org/pdf/10.3802/jgo.2024.35.e100

Reference26 articles.

1. Cancer Statistics, 2021

2. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

3. Immunotherapy for platinum-resistant ovarian cancer

4. A Phase 3 Trial of Bevacizumab in Ovarian Cancer

5. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP